CVS rises on 2025 profit forecast raise

Shares of healthcare conglomerate CVS Health CVS.N rise 7.2% to $71.50 premarket

Co raises full-year profit forecast on strong performance across its businesses

Raises FY adj.profit forecast to $6 to $6.20 per share from $5.75 to $6 per share previously

Reports Q1 adj.profit of $2.25 per share, beating analysts' estimate of $1.70, as per data compiled by LSEG

Co says its pharmacy benefit management unit plans to drop Eli Lilly's LLY.N weight-loss drug Zepbound as a preferred product from its list of drugs eligible for reimbursement, and retain Novo Nordisk's Wegovy

Up to last close, stock up 48.6% YTD